NO2459176T3 - - Google Patents
Info
- Publication number
- NO2459176T3 NO2459176T3 NO10805109A NO10805109A NO2459176T3 NO 2459176 T3 NO2459176 T3 NO 2459176T3 NO 10805109 A NO10805109 A NO 10805109A NO 10805109 A NO10805109 A NO 10805109A NO 2459176 T3 NO2459176 T3 NO 2459176T3
- Authority
- NO
- Norway
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6503—Five-membered rings
- C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Nutrition Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Physiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23022209P | 2009-07-31 | 2009-07-31 | |
| US28803609P | 2009-12-18 | 2009-12-18 | |
| US30211010P | 2010-02-06 | 2010-02-06 | |
| US31287910P | 2010-03-11 | 2010-03-11 | |
| US31850310P | 2010-03-29 | 2010-03-29 | |
| US35954410P | 2010-06-29 | 2010-06-29 | |
| PCT/US2010/043892 WO2011014766A2 (en) | 2009-07-31 | 2010-07-30 | Crystallization method and bioavailability |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO2459176T3 true NO2459176T3 (https=) | 2018-02-24 |
Family
ID=43527595
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO10805109A NO2459176T3 (https=) | 2009-07-31 | 2010-07-30 |
Country Status (20)
| Country | Link |
|---|---|
| US (5) | US8399023B2 (https=) |
| EP (2) | EP2459176B1 (https=) |
| JP (1) | JP5852569B2 (https=) |
| KR (1) | KR101813728B1 (https=) |
| CN (1) | CN102573809B (https=) |
| AU (2) | AU2010278860B2 (https=) |
| CA (1) | CA2769633C (https=) |
| CY (1) | CY1121952T1 (https=) |
| DK (1) | DK2459176T3 (https=) |
| ES (1) | ES2650665T3 (https=) |
| HR (1) | HRP20171755T1 (https=) |
| HU (1) | HUE034784T2 (https=) |
| IL (1) | IL217828B (https=) |
| IN (1) | IN2012DN01216A (https=) |
| LT (1) | LT2459176T (https=) |
| NO (1) | NO2459176T3 (https=) |
| PL (1) | PL2459176T3 (https=) |
| PT (1) | PT2459176T (https=) |
| SI (1) | SI2459176T1 (https=) |
| WO (1) | WO2011014766A2 (https=) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9169279B2 (en) | 2009-07-31 | 2015-10-27 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
| EP3158867B1 (en) | 2009-07-31 | 2018-12-12 | Grünenthal GmbH | A method for increasing the aqueous solubility of a bisphosphonic acid or a bisphosphonate |
| US20160016982A1 (en) * | 2009-07-31 | 2016-01-21 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
| CA2769633C (en) | 2009-07-31 | 2017-06-06 | Thar Pharma, Llc | Crystallization method and bioavailability |
| JP5792748B2 (ja) * | 2010-02-06 | 2015-10-14 | タール ファーマシューティカルズ，インコーポレイテッド | 結晶化法及びバイオアベイラビリティ |
| WO2012071517A2 (en) | 2010-11-24 | 2012-05-31 | Thar Pharmaceuticals, Inc. | Novel crystalline forms |
| US10463682B2 (en) | 2012-05-14 | 2019-11-05 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating low back pain |
| US9901589B2 (en) | 2012-05-14 | 2018-02-27 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| US9675626B2 (en) | 2012-05-14 | 2017-06-13 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| US9949993B2 (en) | 2012-05-14 | 2018-04-24 | Antecip Bioventures Ii Llc | Compositions for administration of zoledronic acid or related compounds for treating low back pain |
| US10028969B2 (en) | 2012-05-14 | 2018-07-24 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| US10413561B2 (en) | 2012-05-14 | 2019-09-17 | Antecip Bioventures Ii Llc | Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases |
| US9956237B2 (en) | 2012-05-14 | 2018-05-01 | Antecip Bioventures Ii Llc | Osteoclast inhibitors for knee conditions |
| US9999629B2 (en) | 2012-05-14 | 2018-06-19 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| US9999628B2 (en) | 2012-05-14 | 2018-06-19 | Antecip Bioventures Ii Llc | Neridronic acid for treating complex regional pain syndrome |
| US9694023B2 (en) | 2012-05-14 | 2017-07-04 | Antecip Bioventures Ii Llc | Methods for the safe administration of imidazole or imidazolium compounds |
| US9925203B2 (en) | 2012-05-14 | 2018-03-27 | Antecip Bioventures Ii Llc | Compositions for administration of zoledronic acid or related compounds for treating low back pain |
| US20140349974A1 (en) * | 2014-08-12 | 2014-11-27 | Antecip Bioventures Ii Llc | Zoledronic acid dosage forms for the treatment of pain |
| US9861648B2 (en) | 2012-05-14 | 2018-01-09 | Antecip Boiventures Ii Llc | Osteoclast inhibitors for knee conditions |
| US9789128B2 (en) | 2012-05-14 | 2017-10-17 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| US10111837B2 (en) | 2012-05-14 | 2018-10-30 | Antecip Bioventures Ii Llc | Dosage forms for oral administration of zoledronic acid or related compounds |
| US9867840B2 (en) | 2014-05-27 | 2018-01-16 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| US10173986B2 (en) | 2012-05-14 | 2019-01-08 | Antecip Bioventures Ii Llc | Methods for the safe administration of imidazole or imidazolium compounds |
| US9700570B2 (en) | 2014-05-27 | 2017-07-11 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| US10004756B2 (en) | 2014-05-15 | 2018-06-26 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| US9956234B2 (en) | 2012-05-14 | 2018-05-01 | Antecip Bioventures Ii Llc | Osteoclast inhibitors for joint conditions |
| US9867839B2 (en) | 2012-05-14 | 2018-01-16 | Antecip Bioventures Ii Llc | Osteoclast inhibitors for joint conditions |
| US8802658B2 (en) * | 2012-05-14 | 2014-08-12 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating disease |
| US10034890B2 (en) | 2012-05-14 | 2018-07-31 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| US10350227B2 (en) | 2012-05-14 | 2019-07-16 | Antecip Bioventures Ii Llc | Neridronic acid for treating complex regional pain syndrome |
| US10039773B2 (en) | 2012-05-14 | 2018-08-07 | Antecip Bioventures Ii Llc | Neridronic acid for treating arthritis |
| US10092581B2 (en) | 2014-05-15 | 2018-10-09 | Antecip Bioventures Ii Llc | Osteoclast inhibitors such as zoledronic acid for low back pain treatment |
| US10016445B2 (en) | 2012-05-14 | 2018-07-10 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| US9770457B2 (en) | 2012-05-14 | 2017-09-26 | Antecip Bioventures Ii Llc | Neridronic acid for treating bone marrow lesion |
| US9827192B2 (en) | 2012-05-14 | 2017-11-28 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| US10080765B2 (en) | 2012-05-14 | 2018-09-25 | Antecip Bioventures Ii Llc | Neridronic acid for treating complex regional pain syndrome |
| US9669040B2 (en) | 2012-05-14 | 2017-06-06 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| US9795622B2 (en) | 2012-05-14 | 2017-10-24 | Antecip Bioventures Ii Llc | Neridronic acid for treating pain associated with a joint |
| US10413560B2 (en) | 2012-05-14 | 2019-09-17 | Antecip Bioventures Ii Llc | Dosage forms for oral administration of zoledronic acid or related compounds for treating disease |
| US8865757B1 (en) | 2014-05-28 | 2014-10-21 | Antecip Bioventures Ii Llp | Therapeutic compositions comprising imidazole and imidazolium compounds |
| US9707245B2 (en) | 2012-05-14 | 2017-07-18 | Antecip Bioventures Ii Llc | Neridronic acid for treating complex regional pain syndrome |
| US9820999B2 (en) | 2012-05-14 | 2017-11-21 | Antecip Bioventures Ii Llc | Neridronic acid for treating complex regional pain syndrome |
| US9782421B1 (en) | 2012-05-14 | 2017-10-10 | Antecip Bioventures Ii Llc | Neridronic acid molecular complex for treating complex regional pain syndrome |
| US9844559B2 (en) | 2012-05-14 | 2017-12-19 | Antecip Bioventures Ii Llc | Neridronic acid for treating bone marrow lesions |
| US9427403B2 (en) * | 2012-05-14 | 2016-08-30 | Antecip Bioventures Ii Llc | Methods for the safe administration of imidazole or imidazolium compounds |
| US10028908B2 (en) | 2012-05-14 | 2018-07-24 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| US9662343B2 (en) | 2012-05-14 | 2017-05-30 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| US9211257B2 (en) | 2012-05-14 | 2015-12-15 | Antecip Bioventures Ii Llc | Osteoclast inhibitors for knee conditions |
| US9616078B2 (en) | 2012-05-14 | 2017-04-11 | Antecip Bioventures Ii Llc | Dosage forms for oral administration of zoledronic acid or related compounds for treating disease |
| US9877977B2 (en) | 2012-05-14 | 2018-01-30 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| US11654152B2 (en) | 2012-05-14 | 2023-05-23 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating disease |
| US10493085B2 (en) | 2012-05-14 | 2019-12-03 | Antecip Bioventures Ii Llc | Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases |
| US9717747B2 (en) | 2012-05-14 | 2017-08-01 | Antecip Bioventures Ii Llc | Osteoclast inhibitors for knee conditions |
| US9289441B2 (en) | 2014-08-08 | 2016-03-22 | Antecip Bioventures Ii Llc | Osteoclast inhibitors such as zoledronic acid for low back pain treatment |
| US9707247B2 (en) | 2012-05-14 | 2017-07-18 | Antecip Bioventures Ii Llc | Compositions for administration of zoledronic acid or related compounds for treating low back pain |
| US10016446B2 (en) | 2012-05-14 | 2018-07-10 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating Paget's disease of bone |
| US9956238B2 (en) | 2014-05-15 | 2018-05-01 | Antecip Bioventures Ii Llc | Compositions for administration of zoledronic acid or related compounds for treating low back pain |
| US9655908B2 (en) | 2012-05-14 | 2017-05-23 | Antecip Bioventures Ii Llc | Neridronic acid molecular complex for treating complex regional pain syndrome |
| US9943531B2 (en) | 2014-08-08 | 2018-04-17 | Antecip Bioventures Ii Llc | Osteoclast inhibitors such as zoledronic acid for low back pain treatment |
| US9827256B2 (en) | 2014-05-27 | 2017-11-28 | Antecip Bioventures Ii Llc | Compositions for administration of zoledronic acid or related compounds for treating lower back pain |
| US9895383B2 (en) | 2012-05-14 | 2018-02-20 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| KR20190009428A (ko) * | 2013-10-25 | 2019-01-28 | 안테씨프 바이오벤쳐스 투 엘엘씨 | 질병의 치료를 위한, 졸레드론산 또는 관련 화합물의 경구 투여용 조성물 |
| US9127069B1 (en) | 2014-06-11 | 2015-09-08 | Antecip Bioventures LLC | Compositions comprising rank/rankl antagonists and related compounds for treating pain |
| US9079927B1 (en) | 2014-05-27 | 2015-07-14 | Antecip Bioventures Ii Llc | Substituted imidazolium compounds for treating disease |
| US9688765B2 (en) | 2014-06-11 | 2017-06-27 | Antecip Bioventures Ii Llc | Methods using RANK/RANKL antagonist antibodies for treating pain |
| CA2997378A1 (en) * | 2015-09-18 | 2017-03-23 | Thar Pharma, Llc | Crystallization method and bioavailability |
| WO2017208070A1 (en) | 2016-05-31 | 2017-12-07 | Grünenthal GmbH | Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis |
| CN112778365A (zh) * | 2020-12-30 | 2021-05-11 | 华南理工大学 | 一种唑来膦酸钙配合物及其制备方法 |
Family Cites Families (142)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3959361A (en) | 1970-03-20 | 1976-05-25 | Joh. A. Benckiser Gmbh | Process of producing amino methylene phosphonic acids |
| US3961934A (en) | 1974-12-19 | 1976-06-08 | Monsanto Company | Method for increasing the sucrose content of growing plants |
| DE3776880D1 (de) | 1986-11-21 | 1992-04-02 | Ciba Geigy Ag | Neue substituierte alkandiphosphonsaeuren. |
| IE912115A1 (en) | 1990-06-25 | 1992-01-01 | Takeda Chemical Industries Ltd | Bisphosphonic acid derivatives, their production and use |
| DE69201725T2 (de) | 1991-02-26 | 1996-04-18 | Procter & Gamble Pharmaceuticals, Inc. (An Ohio Corp.), Norwich, N.Y. | Behandlungsmethoden für osteoporose. |
| US5431920A (en) | 1993-09-21 | 1995-07-11 | Merck Frosst, Canada, Inc. | Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents |
| EP0779812A4 (en) | 1994-09-09 | 1997-09-10 | Procter & Gamble | Methods for the treatment of osteoporosis using bone active phosphonates and parathyroid hormone |
| US6541454B1 (en) | 1995-04-04 | 2003-04-01 | Yissum Research Development Company Of The Hebrew University Jerusalem | Phosphonates, biphosphonates and pharmaceutical compositions containing them |
| GB9516268D0 (en) | 1995-08-08 | 1995-10-11 | Danbiosyst Uk | Compositiion for enhanced uptake of polar drugs from the colon |
| GB9710699D0 (en) | 1997-05-24 | 1997-07-16 | Danbiosyst Uk | Gastro-retentive controlled release system |
| DE69826660T2 (de) | 1997-06-11 | 2005-10-06 | The Procter & Gamble Company, Cincinnati | Filmüberzogene tablette für verbesserte verträglichkeit im oberen magen-darmtrakt |
| EP0998933A1 (de) | 1998-10-09 | 2000-05-10 | Boehringer Mannheim Gmbh | Verfahren zur Herstellung von bisphosphonathaltigen pharmazeutischen Zusammensetzungen zur oralen Applikation |
| US8119159B2 (en) | 1999-02-22 | 2012-02-21 | Merrion Research Iii Limited | Solid oral dosage form containing an enhancer |
| DE60038097T2 (de) | 1999-02-22 | 2009-02-12 | Merrion Research I Ltd. | Feste orale dosierungsform enthaltend einen resorptionsverstärker |
| US7658938B2 (en) | 1999-02-22 | 2010-02-09 | Merrion Reasearch III Limited | Solid oral dosage form containing an enhancer |
| SE9901272D0 (sv) | 1999-04-09 | 1999-04-09 | Astra Ab | New improved formulation |
| EP1210138A4 (en) | 1999-04-22 | 2003-05-07 | Hydro Med Sciences Inc | REGULATED BISPHOSPHONATE ADMINISTRATION |
| KR100763064B1 (ko) | 1999-05-21 | 2007-10-04 | 노파르티스 아게 | 제약 조성물 및 용도 |
| AR021347A1 (es) | 1999-10-20 | 2002-07-17 | Cipla Ltd | Una composicion farmaceutica que contiene acido(s) bisfosfoncio o sal(es) del mismo y un proceso de preparacion de la misma |
| US6936275B2 (en) | 1999-12-20 | 2005-08-30 | Scolr, Inc. | Amino acid modulated extended release dosage form |
| US6677320B2 (en) | 2000-01-20 | 2004-01-13 | Hoffmann-La Roches Inc. | Parenteral bisphosphonate composition with improved local tolerance |
| MXPA02009924A (es) | 2000-04-07 | 2004-08-19 | Univ Texas | Composiones unicas de fosfolipidos de ion anfoterico y bisfosfonatos y uso de las composiciones como sistemas de suministro de bisfosfato con toxicidad gi reducida. |
| US6468559B1 (en) | 2000-04-28 | 2002-10-22 | Lipocine, Inc. | Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods |
| ATE314862T1 (de) * | 2000-05-05 | 2006-02-15 | Hoffmann La Roche | Gelartige pharmazeutische zusammensetzung zur subcutanen anwendung enthaltend bisphosphonsäuren oder deren salze |
| CA2410201C (en) | 2000-06-20 | 2010-10-26 | Novartis Ag | Zoledronic acid or salts thereof for use in the treatment of conditions of abnormally increased bone turnover |
| EP1591122B1 (en) | 2000-06-20 | 2012-09-26 | Novartis AG | Method of administering bisphosphonates |
| US6476006B2 (en) | 2000-06-23 | 2002-11-05 | Teva Pharmaceutical Industries, Ltd. | Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates |
| CA2415643C (en) | 2000-07-17 | 2010-11-16 | Yamanouchi Pharmaceutical Co., Ltd. | Pharmaceutical composition for oral use with improved absorption |
| EP1365769B1 (en) | 2001-02-06 | 2011-01-26 | The Sydney Children's Hospitals Network (Randwick and Westmead) (incorporating The Royal Alexandra Hospital for Children) | A drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis |
| NZ527157A (en) * | 2001-03-01 | 2005-04-29 | Emisphere Tech Inc | Compositions for delivering bisphosphonates |
| NZ528659A (en) | 2001-04-03 | 2005-02-25 | Royal Alexandra Hosp Children | A drug for use in bone grafting |
| SK14792003A3 (sk) | 2001-04-30 | 2004-07-07 | Novologix Gmbh | Použitie látok naviazaných na EF-Tu, antibakteriálny prostriedok s obsahom látok naviazaných na EF-Tu a spôsob identifikácie nových antibakteriálnych účinných látok |
| EP1418897A2 (en) | 2001-05-02 | 2004-05-19 | Novartis AG | Use of bisphosphonates in the treatment of bone metastasis associated with prostate cancer |
| PT1392325E (pt) | 2001-05-02 | 2006-10-31 | Novartis Ag | Metodo de administracao de bifosfonatos por inalacao no tratamento ou na prevencao da reabsorcao ossea e da osteoporose |
| EP1392272B1 (en) | 2001-05-11 | 2014-08-06 | Merrion Research III Limited | Permeation enhancers |
| EP1416919A1 (en) | 2001-07-17 | 2004-05-12 | Teva Pharmaceutical Industries Ltd. | Dosage forms for immediate gastric release of a calcium transport stimulator coupled with delayed gastric release of a bis-phosphonate |
| RU2317819C2 (ru) | 2001-10-19 | 2008-02-27 | Новартис Аг | Фармацевтическая композиция для применения в терапии злокачественных новообразований, включающая комбинацию бифосфоната, ингибитора сох-2 и таксола |
| EP1458400A1 (en) | 2001-12-13 | 2004-09-22 | Merck & Co., Inc. | Liquid bisphosphonate formulations for bone disorders |
| ITMI20020908A1 (it) | 2002-04-29 | 2003-10-29 | Chemi Spa | Processo di preparazione di sodio alendronato |
| RU2387451C2 (ru) | 2002-05-10 | 2010-04-27 | Ф.Хоффманн-Ля Рош Аг | Бисфосфоновые кислоты, предназначенные для лечения и профилактики остеопороза |
| KR100681282B1 (ko) | 2002-05-17 | 2007-02-12 | 테바 파마슈티컬 인더스트리즈 리미티드 | 특정 희석제를 사용하는 비스포스폰산 및 그 염의 제조방법 |
| US20040047835A1 (en) | 2002-09-06 | 2004-03-11 | Cell Therapeutics, Inc. | Combinatorial drug therapy using polymer drug conjugates |
| GB0220885D0 (en) | 2002-09-09 | 2002-10-16 | Novartis Ag | Organic compounds |
| US20040138180A1 (en) | 2002-10-03 | 2004-07-15 | Barr Laboratories, Inc. | Bisphosphonate composition and process for the preparation thereof |
| TW200410701A (en) | 2002-10-15 | 2004-07-01 | Novartis Ag | Method of administering bisphosphonates |
| HRP20041013B1 (hr) | 2002-12-20 | 2013-10-25 | F. Hoffmann - La Roche Ag | Formulacija visoke doze ibandronata |
| US20040230076A1 (en) | 2003-02-27 | 2004-11-18 | Revital Lifshitz-Liron | Process for purification of zoledronic acid |
| JP2007524596A (ja) | 2003-02-28 | 2007-08-30 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | 共結晶医薬組成物 |
| ATE550022T1 (de) | 2003-02-28 | 2012-04-15 | Mcneil Ppc Inc | Pharmazeutische mischkristalle von celecoxib- nicotinamid |
| US20040220264A1 (en) | 2003-03-17 | 2004-11-04 | Yu Ruey J | Bioavailability and improved delivery of acidic pharmaceutical drugs |
| GB0310919D0 (en) | 2003-05-13 | 2003-06-18 | West Pharm Serv Drug Res Ltd | Pharmaceutical compositions |
| WO2005000404A2 (en) | 2003-05-29 | 2005-01-06 | Synta Pharmaceuticals, Corp. | Heterocyclic compounds for preventing and treating disorders associated with excessive bone loss |
| EP1640010A1 (en) * | 2003-07-01 | 2006-03-29 | Astellas Pharma Inc. | Agent inducing increase in bone mass |
| US20050054616A1 (en) | 2003-07-03 | 2005-03-10 | Judith Aronhime | Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation |
| JP4642762B2 (ja) * | 2003-08-21 | 2011-03-02 | サン・ファーマシューティカル・インダストリーズ・リミテッド | ビスホスホン酸化合物の製造方法 |
| US20050119230A1 (en) | 2003-09-18 | 2005-06-02 | Alexandra Glausch | Pharmaceutical products comprising bisphosphonated |
| MY141763A (en) | 2003-09-18 | 2010-06-30 | Novartis Ag | Pharmaceutical products comprising bisphosphonates |
| WO2005027921A1 (en) | 2003-09-19 | 2005-03-31 | Pfizer Products Inc. | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a bisphosphonate |
| WO2005048979A2 (en) | 2003-10-06 | 2005-06-02 | Torrent Pharmaceuticals Limited | Pharmaceutical composition having casing with multiple micro tablets |
| US20050244485A1 (en) | 2003-10-14 | 2005-11-03 | Tsung-Min Hsu | Transdermal administration of hydrophilic drugs using a basic permeation enhancer composition |
| AR046773A1 (es) | 2003-12-23 | 2005-12-21 | Novartis Ag | Formulaciones farmaceuticas de bisfosfonatos |
| WO2005063717A1 (en) | 2003-12-26 | 2005-07-14 | Natco Pharma Limited | An improved process for the preparation of zoledronic acid |
| US20080138390A1 (en) | 2004-04-07 | 2008-06-12 | Tsung-Min Hsu | Transdermal Delivery System For Use With Basic Permeation Enhancers |
| US7645459B2 (en) | 2004-05-24 | 2010-01-12 | The Procter & Gamble Company | Dosage forms of bisphosphonates |
| US20080287400A1 (en) | 2004-05-24 | 2008-11-20 | Richard John Dansereau | Low Dosage Forms Of Risedronate Or Its Salts |
| US7645460B2 (en) | 2004-05-24 | 2010-01-12 | The Procter & Gamble Company | Dosage forms of risedronate |
| NZ551118A (en) | 2004-05-24 | 2010-09-30 | Warner Chilcott Co Llc | Enteric solid oral dosage form of bisphosphonate containing a chelating agent |
| US20080286359A1 (en) | 2004-05-24 | 2008-11-20 | Richard John Dansereau | Low Dosage Forms Of Risedronate Or Its Salts |
| AU2011218625B2 (en) | 2004-05-24 | 2014-03-20 | Theramex HQ UK Limited | Dosage forms of risedronate |
| US20050289182A1 (en) | 2004-06-15 | 2005-12-29 | Sand Hill Systems Inc. | Document management system with enhanced intelligent document recognition capabilities |
| EP1796683A1 (en) | 2004-07-15 | 2007-06-20 | Nanobac Life Sciences | Methods and compositions for the administration of calcium chelators, bisphosphonates and/or citrate compounds and their pharmaceutical uses |
| WO2006020009A1 (en) | 2004-07-23 | 2006-02-23 | The Procter & Gamble Company | Solid oral dosage form of a bisphosphonate containing a chelating agent |
| EP1781258A1 (en) | 2004-08-20 | 2007-05-09 | Mepha AG | Formulations of bisphosphonates |
| US20060068010A1 (en) | 2004-09-30 | 2006-03-30 | Stephen Turner | Method for improving the bioavailability of orally delivered therapeutics |
| US20060134190A1 (en) | 2004-12-16 | 2006-06-22 | Banner Pharmacaps Inc. | Formulations of bisphosphonate drugs with improved bioavailability |
| US20060178439A1 (en) * | 2005-01-04 | 2006-08-10 | Mohakhud Pradeep K | Crystalline form of zoledronic acid |
| KR100815040B1 (ko) | 2005-01-31 | 2008-03-18 | 주식회사종근당 | 비스포스포네이트계 약물의 경구흡수 개선을 위한약제학적 조성물 |
| WO2006087722A1 (en) | 2005-02-17 | 2006-08-24 | Hadasit Medical Research Services And Development Ltd. | Bisphosphonates for treating endometriosis |
| BRPI0606280A2 (pt) | 2005-03-17 | 2009-06-09 | Elan Pharma Int Ltd | composições de bisfosfonato nanoparticulado |
| EP1883644A2 (en) | 2005-05-06 | 2008-02-06 | Medichem, S.A. | Process of making geminal bisphosphonic acids and pharmaceutically acceptable salts and/or hydrates thereof |
| US20070014319A1 (en) | 2005-07-15 | 2007-01-18 | Zetetic Institute | Continuously Tunable External Cavity Diode Laser Sources With High Tuning And Switching Rates And Extended Tuning Ranges |
| AR054673A1 (es) | 2005-07-28 | 2007-07-11 | Gador Sa | Una forma cristalina del acido zoledronico, un proceso para su obtencion y la composicion farmaceutica que la comprende |
| US20070049557A1 (en) | 2005-08-24 | 2007-03-01 | Hashim Ahmed | Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers |
| CN101262856A (zh) | 2005-09-12 | 2008-09-10 | 雷迪博士实验室有限公司 | 唑来膦酸的结晶三水合物 |
| JO3006B1 (ar) | 2005-09-14 | 2016-09-05 | Janssen Pharmaceutica Nv | املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك |
| US7473684B2 (en) | 2005-09-16 | 2009-01-06 | Selamine Limited | Bisphosphonate formulation |
| US20070088161A1 (en) | 2005-10-19 | 2007-04-19 | Stockel Richard F | Novel chelated bisphosphonates for use as pharmaceutical agents |
| EP1963345A2 (en) | 2005-12-16 | 2008-09-03 | Wockhardt Limited | Processes for the preparation of pure zoledronic acid |
| WO2007083240A2 (en) | 2006-01-20 | 2007-07-26 | Aurobindo Pharma Limited | An improved process for the preparation of bisphosphonic acids |
| BRPI0707516A2 (pt) | 2006-02-06 | 2011-05-10 | Cypress Bioscience Inc | composiÇÕes que compreendem um bisfosfonato e um antifolato |
| CA2642321A1 (en) | 2006-02-20 | 2007-08-30 | Alembic Limited | An improved process for the preparation of biphosphonic derivatives |
| US20090137808A1 (en) | 2006-03-21 | 2009-05-28 | Albemarle Corporation | Process for manufacturing bisphosphonic acids |
| BRPI0710503A2 (pt) | 2006-04-07 | 2011-08-16 | Merrion Res Iii Ltd | uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral |
| WO2007124274A1 (en) | 2006-04-21 | 2007-11-01 | The Uab Research Foundation | Treating neoplasms |
| WO2007125521A2 (en) | 2006-05-02 | 2007-11-08 | Ranbaxy Laboratories Limited | Polymorphic form of zoledronic acid and processes for their preparation |
| JP2009539862A (ja) | 2006-06-09 | 2009-11-19 | メリオン リサーチ Ｉｉｉ リミテッド | 強化剤を含む固体経口投与剤形 |
| AU2007304205A1 (en) | 2006-10-05 | 2008-04-10 | Novartis Ag | Pharmaceutical compositions comprising bisphosphonates |
| EP1923394A1 (en) | 2006-11-16 | 2008-05-21 | Sandoz A/S | Reagent and use thereof for the production of bisphosphonates |
| EP2114368A1 (en) * | 2006-11-17 | 2009-11-11 | Besins Healthcare | Pharmaceutical compositions comprising a bisphosphonate compound |
| EP1925621A1 (en) | 2006-11-27 | 2008-05-28 | Novartis AG | Crystalline forms of zoledronic acid |
| US20080139514A1 (en) | 2006-11-29 | 2008-06-12 | Subhash Pandurang Gore | Diphosphonic acid pharmaceutical compositions |
| KR100775440B1 (ko) * | 2006-12-20 | 2007-11-12 | 동우신테크 주식회사 | 리세드로네이트 나트륨 헤미펜타히드레이트의 제조방법 |
| US8974801B2 (en) | 2006-12-21 | 2015-03-10 | Amphastar Pharmaceuticals Inc. | Long term sustained release pharmaceutical composition containing aqueous suspension of bisphosphonate |
| TW200843802A (en) | 2007-02-09 | 2008-11-16 | Drugtech Corp | Compositions for improving gastrointestinal nutrient and drug absorption |
| CA2677670C (en) | 2007-03-20 | 2010-08-03 | Centre De Recherche Sur Les Biotechnologies Marines | Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof |
| US20090023683A1 (en) * | 2007-07-16 | 2009-01-22 | Chandrasekhar Kocherlakota | Complexes comprising zoledronic acid and cyclodextrins |
| WO2009018834A1 (en) | 2007-08-06 | 2009-02-12 | Pharmathen S.A. | Pharmaceutical composition containing bisphosphonate and method for the preparation thereof |
| KR101165455B1 (ko) | 2007-09-10 | 2012-07-12 | 한스바이오메드 주식회사 | 인산칼슘 마이크로스피어 약물전달체 및 이의 제조방법 |
| WO2009042179A1 (en) | 2007-09-24 | 2009-04-02 | Teva Pharmaceutical Industries Ltd. | Crystalline forms of ibandronic acid and processeses for the preparation thereof |
| DK2200588T3 (da) | 2007-09-25 | 2019-07-01 | Solubest Ltd | Sammensætninger, som omfatter lipofile aktive forbindelser, og fremgangsmåde til fremstilling deraf |
| US20090082312A1 (en) | 2007-09-25 | 2009-03-26 | Protia, Llc | Deuterium-enriched zoledronic acid |
| ITPA20070034A1 (it) | 2007-10-30 | 2009-04-30 | Tetrapharm S R L | Bifosfonati geminali, loro preparazione e loro impiego in campo oncologico. |
| WO2009067766A1 (en) | 2007-11-26 | 2009-06-04 | Seeker Wireless Pty Limited | Methods and systems for zone creation and adaption |
| JP5244917B2 (ja) | 2007-11-30 | 2013-07-24 | ノバルティス アーゲー | Ｃ２−ｃ５−アルキル−イミダゾール−ビスホスホネート類 |
| US9457056B2 (en) | 2007-12-04 | 2016-10-04 | Ben-Gurion University Of The Negev Research And Development Authority | Peptides comprising alternating hydrophobic and anionic amino acids for treatment of osteoporosis |
| EP2255199A1 (en) | 2008-02-19 | 2010-12-01 | Jovesis Inc. | Microparticle compositions to modify cancer promoting cells |
| NZ587719A (en) | 2008-02-26 | 2012-04-27 | Takeda Pharmaceutical | Fused heterocyclic derivative and use thereof |
| FR2928270B1 (fr) | 2008-03-10 | 2011-01-21 | Erytech Pharma | Formulation methode pour la prevention ou le traitement des metastases osseuses et autres maladies de l'os |
| WO2009121935A2 (en) | 2008-04-04 | 2009-10-08 | Novartis Ag | Pharmaceutical composition with bisphosphonate |
| JP2009302891A (ja) | 2008-06-13 | 2009-12-24 | Sony Corp | 情報処理装置 |
| JP2011529901A (ja) | 2008-07-31 | 2011-12-15 | 味の素株式会社 | リセドロネートまたはその塩の低投与量形態 |
| US8008329B2 (en) | 2008-08-01 | 2011-08-30 | Dong Wha Pharmaceutical Co., Ltd. | Method of treating or preventing osteoporosis comprising administering to a patient in need thereof an effective amount of pharmacuetical composition comprising benzamidine derivative or it's salt, and bisphosphonate |
| WO2010060619A1 (en) | 2008-11-26 | 2010-06-03 | Synthon B.V. | Process for making zoledronic acid |
| WO2010071866A2 (en) | 2008-12-19 | 2010-06-24 | Nuon Therapeutics, Inc. | Combination therapy for arthritis with tranilast |
| CA2751854A1 (en) | 2009-02-25 | 2010-09-02 | Merrion Research Iii Limited | Composition and drug delivery of bisphosphonates |
| US9169279B2 (en) | 2009-07-31 | 2015-10-27 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
| US20160016982A1 (en) | 2009-07-31 | 2016-01-21 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
| CA2769633C (en) | 2009-07-31 | 2017-06-06 | Thar Pharma, Llc | Crystallization method and bioavailability |
| EP3158867B1 (en) | 2009-07-31 | 2018-12-12 | Grünenthal GmbH | A method for increasing the aqueous solubility of a bisphosphonic acid or a bisphosphonate |
| US20110182985A1 (en) | 2010-01-28 | 2011-07-28 | Coughlan David C | Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof |
| JP5792748B2 (ja) | 2010-02-06 | 2015-10-14 | タール ファーマシューティカルズ，インコーポレイテッド | 結晶化法及びバイオアベイラビリティ |
| WO2011132826A1 (en) | 2010-04-19 | 2011-10-27 | Snu R&Db Foundation | Transdermal drug delivery system and pharmaceutical composition for preventing or treating bone diseases |
| US8946199B2 (en) | 2010-04-26 | 2015-02-03 | Ketan Desai | Co-administration of steroids and Zoledronic acid to prevent and treat side effects from Zoledronic acid infusion |
| WO2012071517A2 (en) | 2010-11-24 | 2012-05-31 | Thar Pharmaceuticals, Inc. | Novel crystalline forms |
| CN102070668B (zh) | 2010-12-23 | 2013-07-24 | 蚌埠丰原医药科技发展有限公司 | 一种利用相转移催化剂制备唑来膦酸及其钠盐的方法 |
| US8993057B2 (en) | 2011-10-22 | 2015-03-31 | Masoud Salavati-Niasari | Method for preparing silica-dysprosium oxide core-shell nanoparticles |
| AU2013262995B2 (en) | 2012-05-14 | 2016-09-01 | Antecip Bioventures Ii Llc | Compositions comprising zoledronic acid or related compounds for relieving inflammatory pain and related conditions |
| US20140349974A1 (en) | 2014-08-12 | 2014-11-27 | Antecip Bioventures Ii Llc | Zoledronic acid dosage forms for the treatment of pain |
| CN103070668A (zh) | 2013-01-02 | 2013-05-01 | 北京工业大学 | 心脏年龄检测仪及其检测方法 |
| US20160243250A1 (en) | 2013-10-04 | 2016-08-25 | The Regents Of The University Of California | Treating inflammation using llp2a-bisphosphonate conjugates and mesenchymal stem cells |
| CA2997378A1 (en) | 2015-09-18 | 2017-03-23 | Thar Pharma, Llc | Crystallization method and bioavailability |
| WO2017208070A1 (en) | 2016-05-31 | 2017-12-07 | Grünenthal GmbH | Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis |
-
2010
- 2010-07-30 CA CA2769633A patent/CA2769633C/en not_active Expired - Fee Related
- 2010-07-30 WO PCT/US2010/043892 patent/WO2011014766A2/en not_active Ceased
- 2010-07-30 AU AU2010278860A patent/AU2010278860B2/en not_active Ceased
- 2010-07-30 DK DK10805109.5T patent/DK2459176T3/en active
- 2010-07-30 KR KR1020127005170A patent/KR101813728B1/ko not_active Expired - Fee Related
- 2010-07-30 US US12/847,568 patent/US8399023B2/en not_active Expired - Fee Related
- 2010-07-30 PT PT108051095T patent/PT2459176T/pt unknown
- 2010-07-30 JP JP2012523084A patent/JP5852569B2/ja not_active Expired - Fee Related
- 2010-07-30 NO NO10805109A patent/NO2459176T3/no unknown
- 2010-07-30 EP EP10805109.5A patent/EP2459176B1/en active Active
- 2010-07-30 PL PL10805109T patent/PL2459176T3/pl unknown
- 2010-07-30 CN CN201080043099.3A patent/CN102573809B/zh not_active Expired - Fee Related
- 2010-07-30 EP EP17180990.8A patent/EP3295935B1/en active Active
- 2010-07-30 ES ES10805109.5T patent/ES2650665T3/es active Active
- 2010-07-30 HR HRP20171755TT patent/HRP20171755T1/hr unknown
- 2010-07-30 HU HUE10805109A patent/HUE034784T2/en unknown
- 2010-07-30 LT LTEP10805109.5T patent/LT2459176T/lt unknown
- 2010-07-30 IN IN1216DEN2012 patent/IN2012DN01216A/en unknown
- 2010-07-30 SI SI201031592T patent/SI2459176T1/en unknown
-
2012
- 2012-01-30 IL IL217828A patent/IL217828B/en not_active IP Right Cessation
-
2013
- 2013-02-13 US US13/766,034 patent/US8933057B2/en not_active Expired - Fee Related
- 2013-03-14 US US13/826,691 patent/US9334296B2/en not_active Expired - Fee Related
-
2016
- 2016-04-19 US US15/132,707 patent/US20170022226A1/en not_active Abandoned
- 2016-08-25 AU AU2016219654A patent/AU2016219654B2/en not_active Ceased
-
2017
- 2017-11-21 US US15/819,191 patent/US10323052B2/en not_active Expired - Fee Related
- 2017-11-28 CY CY20171101247T patent/CY1121952T1/el unknown